Skip to content
Delayed ~15 min

ALMR ALAMAR BIOSCIENCES INC

Permanent stock page ↗

Industrials · Russell 2000

Next earnings: not announced yet

What 7 analyst firms say about ALAMAR BIOSCIENCES INC: their latest ratings, price targets and how far the stock is from them. How it works

28.05 USD+1.15 (+4.26%) today
Price as of 6 Nov 16:00 ET

Analyst window: Latest analyst report within last 1 year

Analyst view · last 1Y

+23.9%to the avg target 34.75 USD+6.70 USD
Buy 4 · Hold 2 · Sell 0

6 rated views · 7 analyst/firm records · 7 firms

Latest report23 Sep 2026avg report date 30 Jul
Target rangeLowest to highest analyst target, not a forecast

Radar score

  • Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8029
  • Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8036

Recent analyst activity · last 90 days

Our tracked history has 5 reports on ALMR from 5 analyst firms in the last 90 days (7 firms in the past year).

Comparing each firm's latest target with its previous one: 3 raised their price target.

No firm's latest available rating differs from its previous one.

Latest observed target change: Leerink Partners raised its target from $35.00 (set 12 May 2026) to $45.00 on 23 Sep 2026.

Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.

FirmAnalystLatest ratingReport dateLatest target (USD)
Bank of America SecuritiesUnnamed analystHold12 May 202627.00 USD
JPMorganCasey WoodringBuy11 Aug 202635.00 USD
Leerink PartnersPuneet SoudaBuy23 Sep 202645.00 USD
StifelDaniel AriasBuy11 Aug 202632.00 USD
TD CowenDaniel BrennanBuy4 Nov 2026Conflicting reports · excluded
Weiss RatingsUnnamed analyst—23 Oct 2026—
Data feed RESEARCHResearch TeamHold13 May 2026—

Partial coverage · checked 6 Nov (6 Nov 2026, 03:13 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.